New Delhi: Dr. Lal PathLabs Ltd (LPL), one of India’s leading diagnostic service providers, has entered into a Memorandum of Agreement (MoA) with the National Research Development Corporation (NRDC) to promote collaboration in the transfer, validation, and commercialization of indigenous diagnostic technologies.
The partnership will enable LPL to obtain non-exclusive licensing access to diagnostic technologies supported by NRDC. In addition, NRDC will extend consultancy support in areas such as technology readiness assessment, intellectual property (IP) management, and design improvement. The agreement will also allow the use of LPL’s NABL and CAP-accredited laboratories for clinical validation and scaling up of innovative diagnostic solutions.
This collaboration seeks to bridge the gap between public research and private healthcare infrastructure, creating an ecosystem where innovations developed by Indian researchers can be rapidly translated into clinically validated and commercially viable diagnostic products.
The initiative is expected to strengthen India’s self-reliance in advanced, affordable diagnostic technologies and foster innovation-led growth in the country’s healthcare sector.
(PSU Watch– India's Business News centre that places the spotlight on PSUs, Bureaucracy, Defence and Public Policy is now on Google News. Click here to follow. Also, join PSU Watch Channel in your Telegram. You may also follow us on Twitter here and stay updated.)